Market Access and Pricing Experts
The balancing act that’s keeping pharma and biotech market access on its toes

The launch of gene therapies introduced new benchmarks for pricing of pharmaceutical interventions. CAR-T cell therapy costs close to $500,000 per patient in the US, and €300,000 in Europe. Zolgensma®, gene therapy for the treatment of spinal muscular atrophy, is (at the time of writing) the most expensive drug in the world at $2.1m. Whilst such companies claim these […]

WHO essential medicine list
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

The World Health Organization (WHO) essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the WHO published the 21st edition of the EML, recommending the inclusion of 28 new medicines.1

Biobetters: Market access opportunity?

Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen. For regulatory approval, biobetters must meet the same data requirements as all other originator products, whilst only a reduced clinical data package is needed for biosimilars (Table 1). This produces time pressure for biobetters […]

Payer-centric post-launch studies for optimal negotiations

Many healthcare stakeholders want to ensure better health outcomes for patients. However, many new and innovative therapies enter the market with evidence gaps in their value proposition. Since tracking and measuring outcomes entails cost and time, many payers decide to go with simpler and more straightforward financial-based contracting agreements, such as discounting, price-volume agreements, and […]

Formulary Lock Out
Formulary lock out in the US

Patients in the US often hear the term ‘drug formulary’ when they go to see their physician. A formulary, essentially, is a list of prescription medicines that are readily available in the hospital or that are covered by the patient’s drug insurance plan. The contents of formularies provide a strong reflection of the business priorities […]

Understanding payer archetypes

One-size-fits-all has become an outdated and non-recommendable approach in pharma business. During the period of blockbuster medical products, this approach was applicable – the wider drug developers cast their net, the greater the chances of expanding their market share. Another merit to this approach was that it made strategy development relatively less complex for pharma […]